Epigenetic modulations in cancer: predictive biomarkers and potential targets for overcoming the resistance to topoisomerase I inhibitors
MM Madkour, WS Ramadan, E Saleh… - Annals of …, 2023 - Taylor & Francis
Introduction Altered epigenetic map is frequently observed in cancer and recent
investigations have demonstrated a pertinent role of epigenetic modifications in the …
investigations have demonstrated a pertinent role of epigenetic modifications in the …
[HTML][HTML] Chemotherapy for relapsed small cell lung cancer: a systematic review and practice guideline
S Cheng, WK Evans, D Stys-Norman… - Journal of Thoracic …, 2007 - Elsevier
Purpose: This clinical practice guideline, based on a systematic review, evaluates
chemotherapy options for patients with relapsed small cell lung cancer (SCLC). Methods …
chemotherapy options for patients with relapsed small cell lung cancer (SCLC). Methods …
[HTML][HTML] A systematic analysis of efficacy of second-line chemotherapy in sensitive and refractory small-cell lung cancer
TK Owonikoko, M Behera, Z Chen, C Bhimani… - Journal of Thoracic …, 2012 - Elsevier
Introduction: Small-cell lung cancer (SCLC) patients unresponsive or relapsing within 90
days after frontline chemotherapy have poor prognosis and are treated with regimens …
days after frontline chemotherapy have poor prognosis and are treated with regimens …
Systemic therapy for small-cell lung cancer: ASCO-Ontario health (cancer care Ontario) guideline
H Khurshid, N Ismaila, J Bian, R Dabney… - Journal of Clinical …, 2023 - ascopubs.org
PURPOSE To provide evidence-based recommendations to practicing clinicians on the
management of patients with small-cell lung cancer. METHODS An Expert Panel of medical …
management of patients with small-cell lung cancer. METHODS An Expert Panel of medical …
Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with …
JR Eckardt, J von Pawel, Z Papai, A Tomova… - Journal of clinical …, 2006 - ascopubs.org
Purpose This open-label, randomized, multicenter phase III study compared oral
topotecan/intravenous cisplatin (TC) with intravenous (IV) etoposide/cisplatin (PE) in …
topotecan/intravenous cisplatin (TC) with intravenous (IV) etoposide/cisplatin (PE) in …
The selective poly (ADP-ribose) polymerase-1 (2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does …
S Miknyoczki, H Chang, J Grobelny, S Pritchard… - Molecular cancer …, 2007 - AACR
The effect of the potent and selective poly (ADP-ribose)(PAR) polymerase-1 [and PAR
polymerase-2] inhibitor CEP-8983 on the ability to sensitize chemoresistant glioblastoma …
polymerase-2] inhibitor CEP-8983 on the ability to sensitize chemoresistant glioblastoma …
Technological and therapeutic advances in advanced small cell lung cancer
C Lum, M Alamgeer - Cancers, 2019 - mdpi.com
Small cell lung cancer (SCLC) accounts for approximately 10–15% of all lung cancers. The
prognosis is poor with median survival in the advanced stage remaining at around 12 …
prognosis is poor with median survival in the advanced stage remaining at around 12 …
Quality-of-life considerations in patients with advanced lung cancer: effect of topotecan on symptom palliation and quality of life
RJ Gralla - The oncologist, 2004 - academic.oup.com
Abstract Learning Objectives After completing this course, the reader will be able to: Explain
the rationale for evaluating quality of life as a treatment end point. Describe the …
the rationale for evaluating quality of life as a treatment end point. Describe the …
Small cell lung cancer: advances in diagnosis and management
AF Chauhan, SV Liu - … in Respiratory and Critical Care Medicine, 2020 - thieme-connect.com
Small cell lung cancer (SCLC) is an aggressive subtype of lung cancer characterized by
rapid growth and early spread. It is a highly lethal disease that typically is diagnosed at a …
rapid growth and early spread. It is a highly lethal disease that typically is diagnosed at a …
Topotecan in the treatment of recurrent small cell lung cancer: an update
A Ardizzoni - The Oncologist, 2004 - academic.oup.com
Abstract Learning Objectives After completing this course, the reader will be able to: Discuss
the results of clinical trials of topotecan both as a single agent and in combination therapy in …
the results of clinical trials of topotecan both as a single agent and in combination therapy in …